The Company Outsmarting Big Pharma in Africa
Harvard Business Review
AUGUST 17, 2012
Most of its sales are in the developing world (including 40% in Africa) — where it sells its HIV drugs for about $350 per year per patient — yet it is as profitable as the pharma giants of Europe, North America, and Japan. and other traditionally developed markets. and other traditionally developed markets.
Let's personalize your content